Logo image of PASG

PASSAGE BIO INC (PASG) Stock Fundamental Analysis

NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD

0.46  -0.01 (-2.13%)

After market: 0.5071 +0.05 (+10.24%)

Fundamental Rating

2

Overall PASG gets a fundamental rating of 2 out of 10. We evaluated PASG against 572 industry peers in the Biotechnology industry. The financial health of PASG is average, but there are quite some concerns on its profitability. PASG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PASG has reported negative net income.
PASG had a negative operating cash flow in the past year.
PASG had negative earnings in each of the past 5 years.
In the past 5 years PASG always reported negative operating cash flow.
PASG Yearly Net Income VS EBIT VS OCF VS FCFPASG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

The Return On Assets of PASG (-61.56%) is comparable to the rest of the industry.
With a Return On Equity value of -94.61%, PASG perfoms like the industry average, outperforming 46.95% of the companies in the same industry.
Industry RankSector Rank
ROA -61.56%
ROE -94.61%
ROIC N/A
ROA(3y)-58.64%
ROA(5y)-47.13%
ROE(3y)-72.49%
ROE(5y)-56.09%
ROIC(3y)N/A
ROIC(5y)N/A
PASG Yearly ROA, ROE, ROICPASG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

PASG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASG Yearly Profit, Operating, Gross MarginsPASG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PASG has been increased compared to 1 year ago.
The number of shares outstanding for PASG has been increased compared to 5 years ago.
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PASG Yearly Shares OutstandingPASG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
PASG Yearly Total Debt VS Total AssetsPASG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -8.95, we must say that PASG is in the distress zone and has some risk of bankruptcy.
PASG has a Altman-Z score of -8.95. This is in the lower half of the industry: PASG underperforms 69.98% of its industry peers.
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.95
ROIC/WACCN/A
WACCN/A
PASG Yearly LT Debt VS Equity VS FCFPASG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.15 indicates that PASG has no problem at all paying its short term obligations.
PASG has a Current ratio of 5.15. This is comparable to the rest of the industry: PASG outperforms 55.32% of its industry peers.
A Quick Ratio of 5.15 indicates that PASG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.15, PASG is in line with its industry, outperforming 57.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 5.15
PASG Yearly Current Assets VS Current LiabilitesPASG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.93% over the past year.
EPS 1Y (TTM)42.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PASG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.19% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.68%
EPS Next 2Y28.03%
EPS Next 3Y16.8%
EPS Next 5Y21.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASG Yearly Revenue VS EstimatesPASG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PASG Yearly EPS VS EstimatesPASG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PASG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PASG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASG Price Earnings VS Forward Price EarningsPASG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PASG Per share dataPASG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PASG's earnings are expected to grow with 16.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.03%
EPS Next 3Y16.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PASG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASSAGE BIO INC

NASDAQ:PASG (3/7/2025, 8:00:02 PM)

After market: 0.5071 +0.05 (+10.24%)

0.46

-0.01 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-12 2025-05-12
Inst Owners49.62%
Inst Owner Change-3.29%
Ins Owners0.16%
Ins Owner Change0.04%
Market Cap28.59M
Analysts85.45
Price Target7.14 (1452.17%)
Short Float %3.29%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.18%
Min EPS beat(2)-32.14%
Max EPS beat(2)17.77%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-32.14%
Max EPS beat(4)26.8%
EPS beat(8)5
Avg EPS beat(8)2.26%
EPS beat(12)8
Avg EPS beat(12)6.53%
EPS beat(16)9
Avg EPS beat(16)2.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.86%
EPS NY rev (1m)0%
EPS NY rev (3m)11.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.56%
ROE -94.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.64%
ROA(5y)-47.13%
ROE(3y)-72.49%
ROE(5y)-56.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 5.15
Altman-Z -8.95
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)604.02%
Cap/Depr(5y)663.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y47.68%
EPS Next 2Y28.03%
EPS Next 3Y16.8%
EPS Next 5Y21.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.97%
EBIT Next 3Y10.1%
EBIT Next 5Y15.94%
FCF growth 1Y56.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.77%
OCF growth 3YN/A
OCF growth 5YN/A